NCI’s PRICING PARADIGM FOR CRADAs: ENTRY PRICES MUST BE IN LINE WITH EXISTING DRUGS, ADDED INDICATIONS SHOULD LOWER PRICES; FREE SUPPLIES IMPORTANT ALSO

More from Archive

More from Pink Sheet